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Recent papers published in Nature by Guardavaccaro et al. and Westbrook et al. describe a nexus of two 
masters of negative regulation of protein levels. Both of these studies establish that the transcriptional 
repressor REST/NRSF is regulated by the highly versatile ubiquitin protein ligase (E3) SCFβ-TrCP, adding a 
new dimension to the relationship between the ubiquitin-proteasome system and epigenetic regulation of 
transcription. These studies elucidate a critical means of regulation for REST, with implications for neuronal 
stem cell differentiation and the dual roles of this protein as a tumor suppressor and oncogene. These 
findings and their significance are discussed herein.REST (repressor element 1 silencing fac-
tor), or NRSF (neuron-restrictive silenc-
ing factor), is a transcriptional repressor 
regulating a myriad of genes. It binds 
to a 21–23 base pair repressor element 
(RE1) of which there are ?1900 copies 
in the human genome. REST plays criti-
cal roles in preventing differentiation and 
maintaining the self-renewal capability of 
neuronal stem cells. In accordance with 
its function in silencing of both neuronal 
and nonneuronal genes, REST is essen-
tial for embryonic development and for a 
number of cellular responses in neurons 
and other cell types.
How REST serves as a master repres-
sor of genes is complex and fascinating. 
This 1097 amino acid protein includes a 
DNA binding domain, followed by lysine- 
and proline-rich domains, sandwiched 
between repressor domains (RD1 and 
RD2) located at its N and C termini (Fig-
ure 1A). These RDs recruit distinct arrays 
of proteins that either repress or epige-
netically silence gene expression. REST 
activity can be modulated by a RE1-like 
dsRNA that turns REST from a repressor 
to an activator. REST interacts with and is 
inactivated by huntington, with Hunting-
ton’s disease mutations abrogating this 
interaction. Recently, proteasomal deg-
radation has been implicated in down-
regulating REST during neural stem cell 
differentiation (Ballas and Mandel, 2005; 
Coulson, 2005; Majumder, 2006; Ooi 
and Wood, 2007).
REST can function as either a tumor 
suppressor or an oncogene depend-
ing on the cellular context. Dimin-
ished REST expression is associated 
with colon cancer and transformation of human mammary epithelial cells 
(HMEC) (Westbrook et al., 2005). High 
levels of forms truncated in the DNA 
binding domain due to alternative splic-
ing, which are similar to a normally 
occurring alternative splice product, are 
implicated in small-cell lung cancer and 
neuroblastoma (Coulson et al., 2000; 
Palm et al., 1999). Likewise, a frameshift 
mutant truncated just beyond the DNA 
binding domain (REST-FS) (Figure 1A) 
is found in colon cancer and can trans-
form epithelial cells (Westbrook et al., 
2005). All of these truncated forms can 
presumably function to some extent as 
“dominant negatives.” An oncogenic 
role for REST has been established in 
medulloblastoma, an aggressive child-
hood malignancy of neural progenitors, 
where high REST levels coupled with 
Myc overexpression drive cells toward 
proliferation and tumorigenesis rather 
than differentiation (Majumder, 2006; 
Ooi and Wood, 2007; Coulson, 2005).
In recent papers by Guardavaccaro et 
al. (2008) and Westbrook et al. (2008), 
using unbiased coimmunoprecipita-
tion and siRNA screens, respectively, 
REST was identified as a substrate for a 
member of the skp1-cullin-F box (SCF) 
family of ubiquitin ligases (E3s). Sub-
strate recognition by SCF E3s is deter-
mined by the F box protein that binds 
the core ligase complex. There are ?70 
human F box proteins, of which only a 
handful have defined substrates. Per-
haps the best known of the SCF E3s is 
SCFβ-TrCP, which recognizes conserved 
phospho-degrons in ?20 substrates, 
including components of the Rel fam-
ily of transcription factors, β-catenin, Cancerand other critical regulatory molecules, 
many of which are involved in cell-cycle 
regulation (Cardozo and Pagano, 2004). 
REST now joins this prominent list of 
β-TrCP substrates that are degraded 
by the proteasome. Interestingly, the 
two groups identified, and established 
as important, two adjacent yet distinct 
β-TrCP binding sites in REST (Figure 
1A). Two similar sites have previously 
been identified in Cdc25A (Busino et 
al., 2003; Ray et al., 2005). Notably, the 
more C-terminal site in REST terminates 
only 30 amino acids from RD2. While 
each group established “their” site as 
critical for REST degradation, neither 
group explored both sites.
Beyond identifying distinct degrons, 
the two groups took different approaches 
to evaluating the relationship of β-TrCP 
with REST and its cellular consequences. 
Westbrook et al. demonstrated, using 
HMEC, that overexpression of β-TrCP, 
which is known to be oncogenic in some 
tissues, results in decreased REST that 
is accompanied by anchorage-indepen-
dent growth, indicating cellular trans-
formation. Transformation was largely 
prevented by re-expression of REST and 
essentially abrogated by a stable degron-
mutant REST. They similarly established 
a causal role between increased β-TrCP, 
decreased REST, and neural differentia-
tion in a well-characterized in vitro model, 
demonstrating that suppression of neural 
differentiation markers by β-TrCP knock-
down was completely prevented by con-
comitant knockdown of REST. Strikingly, 
as embryonic stem cells were stimulated 
to undergo neuronal differentiation, 
β-TrCP expression increased 13-fold,  Cell 13, May 2008 ©2008 Elsevier Inc. 381
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stability. Thus, their findings pro-
vide in vitro genetic data implicat-
ing β-TrCP-mediated ubiquityla-
tion and proteasomal degradation 
of REST in abrogating the tumor 
suppressor role of REST and in 
facilitating neuronal differentiation 
(Figure 1B).
Guardavaccaro et al. focused 
on a better understanding of 
the oncogenic role of REST. In 
assessing multiple nonneuronal 
cell lines, they found REST protein 
levels decreased during the G2 
phase of the cell cycle, which was 
dependent on an intact degron, 
β-TrCP, and proteasome activity. 
Screening important cell-cycle 
regulators, MAD2 expression was 
found to be negatively regulated 
by REST, with the MAD2 RE1 
implicated in this downregulation. 
MAD2 is integral to the mitotic 
checkpoint complex/spindle-
assembly checkpoint, which plays 
a crucial role in maintaining the 
anaphase-promoting complex/
cyclosome (APC/CCdc20) in an inac-
tive form until all chromosomes 
are correctly aligned on mitotic 
spindles. Thereafter, this highly 
complex E3 executes its role in 
initiating sister chromatid separa-
tion and progression to anaphase 
(Musacchio and Salmon, 2007). 
They demonstrated that overex-
pression of either degron-mutant 
REST or oncogenic REST-FS (Fig-
ure 1A) phenocopies MAD2 hap-
loinsufficiency. This is manifested 
by accelerated onset of anaphase 
and by a host of chromosomal 
abnormalities indicative of premature 
APC/CCdc20 activation. This was not 
observed with wild-type REST, which 
was efficiently degraded during G2 even 
when overexpressed. These findings of 
genomic instability are consistent with a 
role for nondegradable REST in tumori-
genesis (Figure 1B).
Collectively, these two studies ele-
gantly establish a direct connection 
between REST and SCFβ-TrCP. Westbrook 
et al. substantially advance our under-
standing of how REST could be regu-
lated during neural development and 
provide evidence for β-TrCP-mediated 
transformation in nonneuronal cells via 
REST degradation. On the other hand, 
Guardavaccaro et al. identify at least 
one mechanism by which stable forms 
of REST may contribute to oncogen-
esis by genetic instability. These find-
ings together at face value lead toward 
different conclusions regarding the 
role of nondegradable REST in cancer. 
However, their results are certainly not 
mutually exclusive given the different 
assays, cells, and mutations utilized, not 
to mention the range of potential REST 
targets and varied expression levels 
of interacting proteins that contribute 
to gene repression/silencing. It 
would therefore be premature to 
conclude a single unifying hypoth-
esis regarding the role of β-TrCP-
mediated degradation REST in 
tumorigenesis. Ultimately, in vivo 
analyses will be required to under-
stand the relative importance of 
these observations. Similarly, 
while the finding of altered MAD2 
expression and accompanying 
chromosomal abnormalities are 
striking, the importance of MAD2 
as a REST target in tumors arising 
from neural stem cells also awaits 
assessment.
An important issue raised 
by these studies relates to the 
nature of the signaling pathways 
that activate REST’s two β-TrCP 
degrons and to what extent they 
are regulated in the context of 
neural differentiation and poten-
tially dysregulated in malignancy. 
Further, given the proximity of 
these two degrons to RD2 (Fig-
ure 1A), one cannot disregard the 
potential for functionally impor-
tant interactions between the two 
degrons, RD2, and their associ-
ated proteins.
In addition to potential impli-
cations in regulating neural stem 
cell differentiation, the findings 
of Westbrook et al. in particular 
suggest the potential for tar-
geting β-TrCP to activate REST 
tumor suppressor function in 
nonneuronal tumors. Such an 
approach, however, must be 
considered with caution, as 
β-TrCP substrates are highly 
varied in function and therefore 
may result in unpredicted effects on 
signal transduction and the cell cycle 
in both tumors and normal tissues. 
Additionally, even when considering 
approaches to increasing REST activity 
directly to enhance its tumor suppres-
sor function, the question of what con-
verts it from a tumor suppressor to an 
oncogene and how this is affected by 
cellular context requires further study. 
Considering the findings of genomic 
instability associated with REST over-
expression, it would appear that even 
in nonneuronal cells too much REST is 
not necessarily a good thing.
Figure 1. Domains and Proposed Functions of REST
(A) Schematic representation of REST/NRSF. REST has N and C 
terminal repressor domains (RD1 and RD2) that serve as scaffolds 
for distinct gene repressor/silencing complexes. The DNA binding 
domain is followed by lysine- and proline-rich domains and two 
β-TrCP binding sites. Alternative splicing leads to truncated forms 
of REST that terminate in the region indicated by the arrow. These 
include a naturally occurring neuron-specific form and forms as-
sociated with small-cell lung cancer and neuroblastoma. The po-
sition of an oncogenic truncation found in colon cancer resulting 
from a frameshift (REST-FS) is also indicated by an arrow.
(B) Proposed functions of REST. (Upper panel) In neuronal stem/
progenitor cells, REST suppresses expression of neuron-specific 
genes maintaining cells in an undifferentiated state. Likewise, in 
normal epithelial cells, REST protein level is maintained, and it func-
tions as a tumor suppressor. REST also suppresses expression of 
MAD2, a component of the mitotic checkpoint complex/spindle-
assembly checkpoint, until degradation of REST by SCFβ-TrCP dur-
ing the G2 phase of the cell cycle. (Lower panel) During neuronal 
differentiation, REST is degraded in a SCFβ-TrCP-dependent manner, 
allowing for expression of genes necessary for differentiation. When 
β-TrCP is overexpressed, as occurs in some epithelial cancers, 
REST levels are dysregulated, contributing to transformation.382 Cancer Cell 13, May 2008 ©2008 Elsevier Inc.
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